Allogene Therapeutics Inc (ALLO) concluded trading on Wednesday at a closing price of $1.2, with 4.81 million shares of worth about $5.77 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -45.21% during that period and on July 02, 2025 the price saw a gain of about 1.69%. Currently the company’s common shares owned by public are about 218.60M shares, out of which, 149.51M shares are available for trading.
Stock saw a price change of -3.23% in past 5 days and over the past one month there was a price change of -5.51%. Year-to-date (YTD), ALLO shares are showing a performance of -48.50% which decreased to -43.66% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.86 but also hit the highest price of $3.78 during that period. The average intraday trading volume for Allogene Therapeutics Inc shares is 3.11 million. The stock is currently trading -7.16% below its 20-day simple moving average (SMA20), while that difference is down -7.61% for SMA50 and it goes to -38.35% lower than SMA200.
Allogene Therapeutics Inc (NASDAQ: ALLO) currently have 218.60M outstanding shares and institutions hold larger chunk of about 65.98% of that.
The stock has a current market capitalization of $262.48M and its 3Y-monthly beta is at 0.34. It has posted earnings per share of -$1.23 in the same period. It has Quick Ratio of 9.71 while making debt-to-equity ratio of 0.23. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALLO, volatility over the week remained 7.77% while standing at 7.71% over the month.
Stock’s fiscal year EPS is expected to rise by 23.59% while it is estimated to increase by 2.30% in next year. EPS is likely to grow at an annualized rate of 8.47% for next 5-years, compared to annual growth of 6.26% made by the stock over the past 5-years.
Coverage by Citizens JMP stated Allogene Therapeutics Inc (ALLO) stock as a Mkt outperform in their note to investors on March 14, 2025, suggesting a price target of $5 for the stock. On August 08, 2024, Oppenheimer Resumed their recommendations, while on May 31, 2024, Piper Sandler Initiated their ratings for the stock with a price target of $11. Stock get a Mkt perform rating from JMP Securities on January 05, 2024.
